Con i nostri dati sosteniamo la ricerca nel campo delle malattie reumatiche infiammatorie. Una panoramica dei progetti di ricerca in corso è disponibile qui.
| Numero del progetto | Titolo | Responsabile del progetto |
|---|---|---|
| 2023_25 | Is peripheral joint response to IL-17 inhibition in the spondyloarthritides site-specific? A European cohort study in psoriatic arthritis and axial spondyloarthritis | Adrian Ciurea, USZ |
| 2023_24 | Validity and reliability of the Disease Activity index for Psoriatic Arthritis (DAPSA) and DAPSA-28 in European patients with Psoriatic Arthritis (PsA) | Michael Nissen |
| 2023_17 | Comparison of DAS 28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index)/ SDAI (Simplified Disease Activity Index) scores: Which score better assesses remission or low disease activity (LDA) in patients with rheumatoid arthritis? | Rüdiger Müller |
| 2023_13 | A comparative cohort analysis of the time to treatment discontinuation and of the effectiveness of upadacitinib and tumor necrosis factor inhibitors in patients with rheumatoid arthritis: analysis of pooled data from RHUMADATA-OBRI-SCQM registries. | Denis Choquette, Axel Finckh, Claire Bombardier |
| 2023_10 | The role of the kynurenine pathway in regulating macrophage function in rheumatoid arthritis | Bojana Müller, Universitätsspital Basel |
| 2023_07 | Digital Biomarker for Monitoring and Predicting Disease Severity in the Daily Lives of Rheumatoid Arthritis Patients | Raphael Micheroli, USZ |
| 2023_05 | Early axial spondyloarthritis: Characterization, response to treatment and spinal radiographic progression in early vs. late disease | Adrian Ciurea, USZ |
| 2023_04 | Cross-country differences in bDMARD prescription behaviour: associations between socioeconomics, real world bDMARD use and disease outcomes | Delphine Courvoisier, HUG |
| 2023_03 | Therapeutic drug monitoring of JAK inhibitors as novel precision medicine instrument for acute and chronic inflammatory disorders | François Girardin |
| 2022_26 | Occurrence and pattern of MRI and radiographic involvement of sacroiliac joints and spine in a European cohort of real-life patients with psoriatic arthritis | Adrian Ciurea, USZ |
| 2022_22 | The MRI equivalent to modified New York criteria-positivity on conventional radiography of the sacroiliac joints | Adrian Ciurea, USZ |
| 2022_21 | Cohort profile: the SCQM polymyalgia rheumatica and giant cell arteritis cohort | Thomas Daikeler |
| 2022_19 | Real world data on Evusheld use and burden of disease of covid19 threat in patients with inflammatory rheumatic diseases | Kim Lauper |
| 2022_18 | The association between MRI sacroiliac joint and spine inflammation and structural lesions, physical function and spinal mobility, and other outcome measures | Adrian Ciurea, USZ |
| 2022_17 | Mechanistic modelling-based prediction of humoral vaccine responses in immuno-modulated patients with inflammatory rheumatic diseases after mRNA COVID-19 vaccination | Christoph Berger, Andrea Rubbert-Roth |
| 2022_16 | Chondrocalcinosis in Rheumatoid Arthritis: an imaging analysis on correlation with disease activity and radiographic progression of Osteoarthritis | Tobias Manigold, Thomas Hügle |
| 2022_15 | Explore the incidence of adverse events in patients treated with conventional and/or biological DMARDs | Michael Nissen |
| 2022_14 | Explore the impact of selected comorbidities and extraarticular manifestations on prescription patterns and treatment effectiveness | Michael Nissen |
| 2022_11 | Automated Dorsal Finger Fold Pattern Recognition on Real World Hand Photos as a Potential Digital Biomarker for the activity of Rheumatoid Arthritis | Thomas Hugle |
| 2022_09 | EuroSpA area E: Data mapping survey study | Michael Nissen |
| 2022_08 | Investigation of ASDAS-ESR cut-offs values for disease activity states in axial spondyloarthritis | Adrian Ciurea, USZ |
| 2022_07 | Comparison of damage progression on MRI and conventional radiography of the sacroiliac joints in axial spondyloarthritis | Raphael Micheroli, USZ |
| 2022_06 | Local vs. central readings of MRIs of the sacroiliac joints in patients with axial spondyloarthritis: investigation of agreement and the need for educational activities for local interpreters” for your information | Adrian Ciurea, USZ |
| 2022_05 | Distribution of sacroiliac joint and spine imaging findings in a large cohort of real-life patients with axial SpA | Adrian Ciurea, USZ |
| 2022_04 | Progression of sacroiliac joint and spinal structural changes in a European cohort of real-life patients with axial spondyloarthritis and psoriatic arthritis: A longitudinal analysis of magnetic resonance and X-ray images. | Adrian Ciurea, USZ |
| 2022_01 | Gender-attributable differences in patient reported outcome measures in axial spondyloarthritis. | Raphael Micheroli |
| 2021_15 | Ultrasonographic differences of synovitis grade between joint locations in rheumatoid arthritis | Raphael Micheroli |
| 2021_14 | Impact of work-related physical stress on the response to different biologics in psoriatic arthritis | Raphael Micheroli |
| 2021_13 | Impact of the Covid-19 pandemic on patient selection and treatment outcomes in spondyloarthritis patients treated with b/tsDMARDs across Europe | Kim Lauper |
| 2021_12 | Analysis of immune-tolerance in individuals with pathogenic mutations in the immunoglobulin kappa (k) light chain | Mike Recher, Diego Kyburz |
| 2021_11 | Treatment retention in SpA patients assessed with methods for interval- censored time-to-event data | Myriam Riek, Seraphina Kissling, Adrian Ciurea |
| 2021_09 | A potential role of Chlamydia infection in Rheumatoid Arthritis development | Céline Lamacchia |
| 2021_08 | Patient Clusters in Rheumatoid Arthritis Identified by Deep Learning Respond Differently to Biologic or Targeted Synthetic DMARDs | Thomas Huegle |
| 2021_07 | Impact of national treatment guidelines, schedules of reimbursement and gross domestic product on treatment outcomes in patients treated with b/tsDMARDs across European observational spondyloarthritis registries | Adrian Ciurea |
| 2021_05 | Understanding the impact of COVID-19 on the anti-apoA-1 IgG response in inflammatory rheumatism disorders | Nicolas Vuilleumier, Axel Finckh |
| 2021_04 | Understanding the heterogeneity in patient populations across EuroSpA registries - the role of national access and treatment guidelines | Michael Nissen |
| 2021_03 | Patient reported outcomes, drug adherence and clinical effectiveness of secukinumab in patients with psoriatic arthritis and axial spondylarthritis up to24 months: Results from the EuroSpA collaboration. | Burkhard Möller |
| 2021_02 | Is uveitis associated with a more severe axial disease phenotype in axial spondyloarthritis? | Adrian Ciurea |
| 2021_01 | Investigating drug-induced Chronic Kidney Disease using a pharmacogenomics approach in a multicentric framework Project | Alexander Leichtle, Burkhard Möller |
| 2020_21 | Comparison of drivers of the associations of obesity and rheumatoid arthritis disease activity and of obesity and erosive progression | Andrea Burden, Thomas Huegle |
| 2020_20 | Treatment of peripheral arthritis in the spondyloarthritides: Joint-specific response to TNF inhibitors? | Adrian Ciurea |
| 2020_19 | Enthesitis in psoriatic arthritis and axial spondyloarthritis: Pattern, risk factors, and effectiveness of tumor necrosis factor inhibitors - A EuroSpA collaboration study | Michael Nissen |
| 2020_17 | Real-world dynamics of anti-S1-binding antibodies after COVID-19 vaccination in patients with inflammatory rheumatic diseases | Andrea Rubbert-Roth, Axel Finckh |
| 2020_16 | Sex and gender differences in response to biologics among patients with rheumatoid arthritis in Switzerland. | Andrea Burden, Axel Finckh, Rafi Micheroli, Burkhard Möller |
| 2020_12 | Description and assessment of treatment gaps in rheumatoid arthritis advanced treatment | Andrea Burden, Axel Finckh, Thomas Hugle |
| 2020_11 | EuroSpA-D: Handling of missing component values in patient-reported outcomes | Stylianos Georgiadis, Myriam Riek, Swiss PI (Micheal Nissen) |
| 2020_09 | Vaccination in patients with rheumatic diseases | Kim Lauper |
| 2020_06 | Psoriasis and Axial Involvement in Spondyloarthritis | Adrian Ciurea |
| 2020_04 | Effectiveness of Abatacept and alternative biologic antirheumatic agents according to the shared epitope: The EASE study | Axel Finckh |
| 2020_03 | Risk factors of infection with SARS-CoV-2 and of a serious course of COVID-19 in inflammatory rheumatic diseases in Switzerland | Axel Finckh |
| 2020_02 | The effectiveness of a therapeutic change in RA patients with radiographic progression despite low disease activity | Ruediger Mueller, Lena Brandt |
| 2020_01 | Prediction of erosions in RA by different modifications of the standard SONAR score | Burkhard Moeller |
| 2019_24 | Prediction of remission, response and retention in patients with psoriatic arthritis and axial spondyloarthritis treated with TNF-inhibitors | Michael Nissen, Adrian Ciurea, Burkhard Moeller |
| 2019_22 | Response tolerance measures in rheumatology | Myriam Riek |
| 2019_21 | Comparative treatment efficacy in rheumatoid arthritis with and without concomitant Sjoegren syndrome (CoRASS) | Lisa Christ, Florian Kollert, Burkhard Möller |
| 2019_20 | Differences in burden of disease, treatment standard and response in patients with Psoriasis Arthritis in case of fulfilling vs not-fulfilling RCT joint count criteria | Burkhard Moeller |
| 2019_18 | SONAR SpA Validation study | Michael Nissen, Pascal Zufferey |
| 2019_16 | Predictors for loss of productivity and the effect of b/tsDMARD treatment on loss of productivity in Swiss patients with rheumatoid arthritis | Diego Kyburz |
| 2019_13 | Development of a prediction score for response to biological or targeted synthetic DMARDs in patients with inflammatory rheumatic diseases by combining clinical and -omics data | Britta Maurer, Caroline Ospelt |
| 2019_12 | Real world effectiveness of baricitinib in the Swiss RA registry | Axel Finckh |
| 2019_11 | European collaborative analysis of real-world effectiveness of JAKinhibs versus anti-TNF agents and other bDMARDs (Jak-pot) | Kim Lauper, HUG |
| 2019_10 | Gender differences in Biologicals and targeted synthetic Disease Modifying Anti-Rheumatic Drugs in Spondyloarthritis and psoriatic arthritis | Michael Nissen, Adrian Ciurea, Burkhard Moeller |
| 2019_09 | Quantifying the effects of lifestyle factors in relation to outcome from bDMARD therapy amongst patients with axSpA and PsA | Michael Nissen, Adrian Ciurea, Burkhard Moeller |
| 2019_08 | SYSCID: Discovering new biomarkers by large “multi-omics” analysis to identify individuals in pre-clinical stages of Rheumatoid Arthritis | C. Lamacchia, Axel Finckh |
| 2019_06 | The impact of body mass index on the effectiveness of in inflammatory rheumatic conditions | Andrea Burden, Axel Finckh |
| 2019_04 | Multimodal-based disease activity indices und risk of progression in rheumatoid arthritis | Giorgio Tamborrini (now Pascal Zufferey), P. Mandl |
| 2019_03 | Effectiveness of TNFi versus OMA biologica in JAK-IR patients with Rheumatoid arthritis, an observational study | Diego Kyburz |
| 2018_18 | Deep learning for the prediction of radiographic progression in rheumatoid arthritis | Thomas Huegle, Maria Kalweit |
| 2018_16 | Comparative efficacy of TNF-inhibitors (TNFi) versus other mode of action (OMA) biological DMARDs in PsA -- an observational study | Burkhard Moeller |
| 2018_09 | Bone health in PsA patients | Diana Dan, Berengere Aubry-Rozier, Daniel Aeberli |
| 2018_07 | Translating humoral immunity against apolipoprotein A1 from an emerging CV risk factor to cardiovascular risk stratification tool in IRD | Cem Gabay, Nicolas Vuilleumier |
| 2018_04 | Effect of rheumatoid arthritis treatments on the incidence of fragility /low trauma fracture | Diana Dan |
| 2018_03 | Retention and effectiveness of TNF inhibitor treatment in axial spondyloarthritis and psoriatic arthritis: an analysis from the EuroSpA collaboration | Michael Nissen, Adrian Ciurea, Cem Gabay, Burkhard Moeller |
| 2018_02 | Patient reported outcomes in patients with axial spondyloarthritis and psoriatic arthritis starting treatment with TNF inhibitors: an analysis from the EuroSpA collaboration | Michael Nissen, Adrian Ciurea, Cem Gabay, Burkhard Moeller |
| 2017_08 | COmPASS II weather sensitivity | Ulrich Walker |
| 2017_07 | COmPASS II treatment response kinetics | Ulrich Walker |
| 2017_06 | COmPASS II socioeconomic | Ulrich Walker |
| 2017_05 | COmPASS II self monitoring and feedback | Ulrich Walker |
| 2017_04 | COmPASS II correlation and fluctuation | Ulrich Walker |
| 2016_14 | The TOcilizumab Collaboration of European Registries in RA (TOCERRA) – comparative effectiveness of tocilizumab (MADACTA) | Cem Gabay, Kim Lauper |
| 2016_12 | Tenosynovitis in Rheumatoid Arthritis: Prevalence, Determinants and Outcome of Tenosynovitis detected in the SONAR-Ultrasound examination in the SCQM Cohort. | Raphael Micheroli, Giorgio Tamborrini |
| 2015_09 | Analysis of fine anti-citrullinated peptide antibody specificities, anti-carbamylated peptide antibodies and genetic characteristics in psoriatic arthritis patients | Michael Nissen |
| 2015_07 | Dosage adjustment of anti-tumor necrosis factor-alpha inhibitors in axial spondyloarthritis | Adrian Ciurea |
| 2015_03 | Impact of axSpA on work participation and the role of anti-TNF treatment | Adrian Ciurea |
| 2014_08 | The effect of body mass index on the course of disease activity in axial spondyloarthritis | Adrian Ciurea, Raphael Micheroli |
| 2014_06 | Anemia and perceived disease burden in axial spondyloarthritis | Adrian Ciurea, Anne Hofmann, Raphael Micheroli |
| 2014_05 | Regular exercise and functional outcomes in axial spondyloarthritis | Adrian Ciurea, Mauro Bachmann |
| 2013_06 | Gender differences in the SCQM axial SpA cohort | Adrian Ciurea |
| 2011_02 | Predictors for duration of remission after discontinuation of biologics therapy | Diego Kyburz |
I progetti di cooperazione internazionale sono elencati solo a titolo informativo. Si prega di notare che l'inclusione di personale aggiuntivo nei progetti internazionali spesso non è possibile a causa delle dimensioni limitate del gruppo di progetto per paese.